Our Latest Stories
Our Science
October 8, 2025
Modulus: Redefining the Future of Biopharma Manufacturing
United by Purpose
Each of us plays a unique role in bringing our purpose to life.
About Us
Who We Are
We are an R&D driven,
AI-powered biopharma company committed to improving people’s lives and creating compelling growth.
Our Pipeline
5
Therapeutic areas
82
Compounds in clinical development
24
Clinical trials in phase 3
Pursue Progress. Discover Extraordinary.
Better is out there. Better medications, better outcomes, better science. It's all down to people like you, from different backgrounds, in different locations, doing different roles. Take the most important step in your career: help us change the lives of people, families and communities for the better.
Our Latest Press Releases
October 17, 2025
Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
October 17, 2025
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
October 15, 2025
Communiqué de presse : Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes
October 8, 2025
Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors